LUPIN Latest Share Price (LUPIN)
TODAY IN ONE LINE
LUPIN edged up 0.8% on average volume, outperforming Nifty's -0.3% move.
With a market cap of ₹95,835.94 Cr., it trades at a P/E of 17.33. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
LUPIN flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 89.0% YoY
- ●High Capital EfficiencyROCE of 23.5% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 23.8%
- ●Healthy Operating MarginsOPM is structurally strong at 26.1%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.26x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 13.3% YoY
- ●Low Promoter HoldingPromoters hold only 0.3%
Latest LUPIN News
What changed recently?
Recent events, corporate actions, and announcements.
LUPIN valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for LUPIN, framed against the sector median so the premium or discount is obvious at a glance.
LUPIN trades at a P/E of 17.33× and P/B of 4.27×, against the Healthcare sector median P/E of 41.12×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
LUPIN technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for LUPIN — derived from the latest tape, not yesterday's close.
LUPIN last traded at ₹2,095 with an intraday range of ₹2,058–₹2,108.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2095.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2217.33 | +122.33 | +5.84% |
| R3 | 2166.83 | +71.83 | +3.43% |
| R2 | 2137.67 | +42.67 | +2.04% |
| R1 | 2116.33 | +21.33 | +1.02% |
| PIVOT | 2087.17 | -7.83 | -0.37% |
| CURRENT | 2095.00 | — | — |
| S1 | 2065.83 | -29.17 | -1.39% |
| S2 | 2036.67 | -58.33 | -2.78% |
| S3 | 2015.33 | -79.67 | -3.80% |
| S4 | 1964.83 | -130.17 | -6.21% |
LUPIN is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹2058–₹2079.1
Trading Inside opening range
LUPIN financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for LUPIN — consolidated or standalone — with margins, YoY growth and key ratios inline.
LUPIN reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹95,835.94 Cr. and reported EPS of ₹59.37.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 22,708 | 27,958 ▲ 23.1% |
| Sales Growth YoY %Derived | 13.48% | 23.12% |
| Other Income | 196 | 424 ▲ 116.8% |
| Total Income | 22,904 | 28,382 ▲ 23.9% |
| 6,842 | 7,326 ▲ 7.1% | |
| Gross ProfitDerived | 15,866 | 20,632 ▲ 30.0% |
| Gross Margin %Derived | 69.87% | 73.79% |
| 10,582 | 11,816 ▲ 11.7% | |
| EBITDA (Operating Profit)Derived | 5,283 | 8,816 ▲ 66.9% |
| OPM %Derived | 23.27% | 31.53% |
| 1,464 | 1,252 ▼ 14.5% | |
| Profit Before Tax (PBT) | 4,015 | 6,873 ▲ 71.2% |
| 709 | 1,517 ▲ 114.1% | |
| Effective Tax %Derived | 17.65% | 22.07% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 3,306 | 5,355 ▲ 62.0% |
| Less: Non-controlling Interests | 25 | 23 ▼ 8.2% |
| Net Profit (Owner's PAT)Derived | 3,282 | 5,333 ▲ 62.5% |
| Net Profit Margin %Derived | 14.45% | 19.07% |
| PAT Growth YoY %Derived | 71.41% | 62.51% |
| Earnings Per Share (EPS ₹) | 71.88 | 116.65 ▲ 62.3% |
| Diluted Shares Outstanding (Cr) | 46 | 46 ▲ 0.1% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | -91 | 440 ▲ 581.5% |
| Total Expenses (incl. D&A & Interest) | 18,889 | 21,510 ▲ 13.9% |
| Material Cost % of RevenueDerived | 19.63% | 16.53% |
| Employee Cost % of RevenueDerived | 17.46% | 16.36% |
| Other Cost % of RevenueDerived | 29.14% | 25.90% |
| Interest Coverage (x)Derived | 13.95x | 17.12x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 15,560 | 16,369 ▲ 5.2% | 15,375 ▼ 6.1% | 15,163 ▼ 1.4% | 16,405 ▲ 8.2% | 16,642 ▲ 1.4% | 20,011 ▲ 20.2% | 22,708 ▲ 13.5% | 27,958 ▲ 23.1% | |
| Sales Growth YoY %Derived | — | 5.20% | -6.08% | -1.38% | 8.19% | 1.44% | 20.25% | 13.48% | 23.12% | |
| Other Income | 395 | 713 ▲ 80.6% | 484 ▼ 32.1% | 136 ▼ 71.8% | 142 ▲ 4.0% | 73 ▼ 48.2% | 120 ▲ 63.8% | 196 ▲ 63.0% | 424 ▲ 116.8% | |
| Total Income | 15,955 | 17,082 ▲ 7.1% | 15,859 ▼ 7.2% | 15,299 ▼ 3.5% | 16,547 ▲ 8.2% | 16,715 ▲ 1.0% | 20,131 ▲ 20.4% | 22,904 ▲ 13.8% | 28,382 ▲ 23.9% | |
5,274 | 5,846 ▲ 10.8% | 5,431 ▼ 7.1% | 5,362 ▼ 1.3% | 6,481 ▲ 20.9% | 6,780 ▲ 4.6% | 6,643 ▼ 2.0% | 6,842 ▲ 3.0% | 7,326 ▲ 7.1% | ||
| Gross ProfitDerived | 10,285 | 10,524 ▲ 2.3% | 9,944 ▼ 5.5% | 9,801 ▼ 1.4% | 9,924 ▲ 1.3% | 9,862 ▼ 0.6% | 13,367 ▲ 35.5% | 15,866 ▲ 18.7% | 20,632 ▲ 30.0% | |
| Gross Margin %Derived | 66.10% | 64.29% | 64.68% | 64.64% | 60.49% | 59.26% | 66.80% | 69.87% | 73.79% | |
7,382 | 7,990 ▲ 8.2% | 7,589 ▼ 5.0% | 7,234 ▼ 4.7% | 9,637 ▲ 33.2% | 8,064 ▼ 16.3% | 9,557 ▲ 18.5% | 10,582 ▲ 10.7% | 11,816 ▲ 11.7% | ||
| EBITDA (Operating Profit)Derived | 2,903 | 2,533 ▼ 12.7% | 2,355 ▼ 7.1% | 2,567 ▲ 9.0% | 287 ▼ 88.8% | 1,798 ▲ 526.0% | 3,811 ▲ 111.9% | 5,283 ▲ 38.7% | 8,816 ▲ 66.9% | |
| OPM %Derived | 18.66% | 15.48% | 15.32% | 16.93% | 1.75% | 10.80% | 19.04% | 23.27% | 31.53% | |
-174 | 1,057 ▲ 706.8% | 581 ▼ 45.0% | 1,028 ▲ 76.9% | 1,801 ▲ 75.2% | 1,155 ▼ 35.9% | 1,508 ▲ 30.6% | 1,464 ▼ 2.9% | 1,252 ▼ 14.5% | ||
| Profit Before Tax (PBT) | 543 | 1,517 ▲ 179.3% | 753 ▼ 50.3% | 1,675 ▲ 122.4% | -1,373 ▼ 181.9% | 716 ▲ 152.2% | 2,422 ▲ 238.1% | 4,015 ▲ 65.8% | 6,873 ▲ 71.2% | |
288 | 902 ▲ 212.6% | 1,157 ▲ 28.3% | 449 ▼ 61.2% | 137 ▼ 69.4% | 269 ▲ 96.0% | 487 ▲ 81.1% | 709 ▲ 45.6% | 1,517 ▲ 114.1% | ||
| Effective Tax %Derived | 53.10% | 59.43% | 153.61% | 26.78% | -9.99% | 37.52% | 20.09% | 17.65% | 22.07% | |
| Profit/Loss from Discontinued Ops | — | — | 130 | — ▼ 100.0% | — | — | — | — | — | |
| Total Profit for Period | 258 | 615 ▲ 138.2% | -270 ▼ 143.8% | 1,228 ▲ 555.2% | -1,509 ▼ 222.9% | 448 ▲ 129.7% | 1,936 ▲ 332.3% | 3,306 ▲ 70.8% | 5,355 ▲ 62.0% | |
| Less: Non-controlling Interests | 7 | 9 ▲ 26.0% | 3 ▼ 69.8% | 11 ▲ 322.2% | 19 ▲ 63.9% | 18 ▼ 5.7% | 21 ▲ 19.8% | 25 ▲ 16.8% | 23 ▼ 8.2% | |
| Net Profit (Owner's PAT)Derived | 251 | 607 ▲ 141.4% | -272 ▼ 144.9% | 1,217 ▲ 546.5% | -1,528 ▼ 225.6% | 430 ▲ 128.1% | 1,914 ▲ 345.1% | 3,282 ▲ 71.4% | 5,333 ▲ 62.5% | |
| Net Profit Margin %Derived | 1.61% | 3.71% | -1.77% | 8.02% | -9.31% | 2.58% | 9.57% | 14.45% | 19.07% | |
| PAT Growth YoY %Derived | — | 141.40% | -144.92% | 546.47% | -225.61% | 128.15% | 345.15% | 71.41% | 62.51% | |
| Earnings Per Share (EPS ₹) | 5.56 | 13.40 ▲ 141.0% | -6.02 ▼ 144.9% | 26.81 ▲ 545.3% | -33.62 ▼ 225.4% | 9.45 ▲ 128.1% | 42.01 ▲ 344.6% | 71.88 ▲ 71.1% | 116.65 ▲ 62.3% | |
| Diluted Shares Outstanding (Cr) | 45 | 45 ▲ 0.1% | 45 ▲ 0.1% | 45 ▲ 0.2% | 45 ▲ 0.2% | 45 ▲ 0.1% | 46 ▲ 0.2% | 46 ▲ 0.2% | 46 ▲ 0.1% | |
| Share of Profit from Associates/JVs | 4 | — ▼ 100.0% | 4 | 1 ▼ 66.2% | 0 ▼ 72.9% | — ▼ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | 138 | -234 ▼ 269.4% | -608 ▼ 160.1% | 262 ▲ 143.1% | 104 ▼ 60.3% | 24 ▼ 76.7% | 38 ▲ 55.2% | -91 ▼ 343.3% | 440 ▲ 581.5% | |
| Total Expenses (incl. D&A & Interest) | 15,411 | 15,565 ▲ 1.0% | 15,105 ▼ 3.0% | 13,624 ▼ 9.8% | 17,920 ▲ 31.5% | 15,999 ▼ 10.7% | 17,709 ▲ 10.7% | 18,889 ▲ 6.7% | 21,510 ▲ 13.9% | |
| Material Cost % of RevenueDerived | 18.99% | 21.75% | 20.58% | 20.90% | 19.72% | 22.16% | 20.70% | 19.63% | 16.53% | |
| Employee Cost % of RevenueDerived | 18.41% | 19.25% | 19.43% | 18.64% | 18.22% | 18.55% | 17.46% | 17.46% | 16.36% | |
| Other Cost % of RevenueDerived | 29.03% | 29.56% | 29.94% | 29.07% | 40.52% | 29.90% | 30.29% | 29.14% | 25.90% | |
| Interest Coverage (x)Derived | 8.89x | 4.71x | 3.81x | 11.94x | -9.61x | 3.34x | 8.39x | 13.95x | 17.12x |
LUPIN segment analysis : revenue and profit mix.
Disclosed business segments at LUPIN with their share of revenue and profit, switchable between consolidated and standalone reporting.
LUPIN discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for LUPIN.
Our AI distills the core fundamental drivers supporting LUPIN, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
LUPIN's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 23 (~0.6× the sector multiple of 41.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 19% would indicate weaker capital compounding.
LUPIN peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — LUPIN is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
LUPIN chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for LUPIN — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
LUPIN delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for LUPIN over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in LUPIN stood at 59.8% of traded volume, against a 20-day average of 57.8%.
LUPIN announcements: results, concalls, ratings, M&A.
Filings LUPIN sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
LUPIN files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 303 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets.
Press Release
Lupin Limited has informed the Exchange regarding a press release dated September 04, 2026, titled "Lupin Receives U.S. FDA Approval for Modafinil…
General Updates
Lupin Limited has informed the Exchange about ESG Rating by Crisil ESG Ratings and Analytics Ltd.
ESOP/ESOS/ESPS
Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares.
General Updates
Lupin Limited has informed the Exchange about ESG Rating by ESG Risk Assessments and Insights Limited.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
LUPIN dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue LUPIN has declared, sequenced by announce and record date.
LUPIN corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About LUPIN: business, sector, key facts.
What LUPIN does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
LUPIN operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: LUPIN, BSE: 500257.
Lupin Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global presence. Established in 1968 (formerly Lupin Chemicals Limited), the company's core business involves the entire pharmaceutical value chain, from drug discovery and development to manufacturing, marketing, and sales.
Lupin's product portfolio is extensive and diverse, encompassing branded and generic formulations, biosimilars, over-the-counter medications, and specialty drugs. A significant portion of their business centers around the production and supply of Active Pharmaceutical Ingredients (APIs), the fundamental building blocks of many pharmaceutical products. This vertical integration allows for greater control over quality and cost.
The company caters to a wide range of therapeutic areas, reflecting a commitment to addressing diverse health needs. These areas include, but are not limited to, anti-tuberculosis treatments, diabetes management, cardiovascular health, respiratory diseases (COPD and asthma), women's health, central nervous system disorders, oncology, immunology, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal health, anti-infective therapies, and nonsteroidal anti-inflammatory drugs. This broad therapeutic focus positions Lupin as a significant player in the global pharmaceutical market.
Beyond its core manufacturing and distribution activities, Lupin is also engaged in bio-clinical research. This commitment to research and development underpins their ability to innovate and bring new and improved treatments to market. Furthermore, the company's operational network includes laboratories, collection centers (LupiMitra), and pickup points, suggesting a robust infrastructure designed to support its extensive operations and reach a wide patient base.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about LUPIN (LUPIN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of LUPIN (LUPIN)?
The current share price of LUPIN (LUPIN) is ₹2,095.00. Today, the stock has gained by ₹17.20 (0.83%), trading in a range of ₹2,058.00 to ₹2,108.50. The stock opened at ₹2,064.00 with a trading volume of 6,21,899 shares.
02Is LUPIN stock a good investment for long-term?
LUPIN can be considered for long-term investment based on several factors. The company has a market capitalization of ₹95,835.94 Cr., P/E ratio of 17.33, ROE of 23.79%, and ROCE of 23.47%. The dividend yield stands at 0.86%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of LUPIN stock?
The 52-week high price of LUPIN (LUPIN) is ₹2,529.50, while the 52-week low is ₹1,900.00. Currently trading at ₹2,095.00, the stock is 10.26% above its 52-week low and 17.18% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy LUPIN stock at the current price?
Whether to buy LUPIN stock at ₹2,095.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 17.33 and P/B ratio of 4.27. Today's performance shows a gain of 0.83%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of LUPIN and when is the next dividend?
LUPIN offers a dividend yield of 0.86%, which means for every ₹100 invested at the current price of ₹2,095.00, you can expect to receive approximately ₹0.86 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of LUPIN?
LUPIN's key financial metrics include: P/E Ratio: 17.33, P/B Ratio: 4.27, ROE: 23.79%, ROCE: 23.47%, Dividend Yield: 0.86%, EPS: ₹59.37, Book Value: ₹492.38, and Debt-to-Equity: 0.26. The company's market cap stands at ₹95,835.94 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is LUPIN stock performing today in the market?
LUPIN stock opened at ₹2,064.00 and is currently trading at ₹2,095.00, showing a gain of ₹17.20 (0.83%). The intraday high is ₹2,108.50 and low is ₹2,058.00. The trading volume stands at 6,21,899 shares, indicating moderate market participation today.
08What is the P/E ratio of LUPIN and what does it indicate?
LUPIN has a Price-to-Earnings (P/E) ratio of 17.33, which means investors are willing to pay 17.33 for every ₹1 of earnings. With an EPS of ₹59.37, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about LUPIN (LUPIN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.